이원소식
12715

작성자 : 이원성형외과

[헬스경향]IMCAS 2025: Advancements in Filler Safety and Innovation

본문

IMCAS 2025: Advancements in Filler Safety and Innovation - 헬스경향

원문요약
The IMCAS World Congress 2025 (IMCAS 2025), one of the world’s leading medical aesthetics

843be73ee805e67d797f2f1abe2c0ba0_1738905
Dr. Lee is giving a lecture on “Ocular Complication Induced by HA Filler and Possible Treatment” at IMCAS 2025.

 

The IMCAS World Congress 2025 (IMCAS 2025), one of the world’s leading medical aesthetics conferences, is concluding its final day with an atmosphere full of enthusiasm and excitement.

 


This year’s event has attracted a record-breaking 20,000 participants, with over 350 companies showcasing cutting-edge products and technologies, and more than 900 speakers delivering in-depth lectures.

At this prestigious conference, Dr. Won Lee of Yonsei E1 Plastic Surgery delivered a lecture titled “Ocular Complication Induced by HA Filler and Possible Treatment.”

Hyaluronic acid (HA) fillers are widely used for wrinkle reduction and facial contour enhancement, but unexpected complications may arise during the procedure. Among these, ocular complications caused by vascular occlusion can be particularly severe, requiring immediate intervention.

Dr. Lee emphasized that the choice of filler is a key factor in both preventing and treating complications, stating:
“Using a filler with the lowest level of MoD (Degree of Modification), such as Lorient Filler, is essential. If an ocular complication occurs, this allows for effective dissolving of the filler within the blood vessels, enabling successful treatment.”

MoD (Degree of Modification) refers to the extent of chemical modification in hyaluronic acid to achieve specific properties such as durability, flexibility, and performance across various facial areas.

However, Lorient Filler is designed with the lowest MoD, minimizing chemical modifications while maintaining superior gel properties. This ensures that the filler integrates seamlessly with the skin’s natural tissue while remaining easily dissolvable with hyaluronidase when necessary.

As a highly purified premium HA filler, Lorient Filler offers a uniform particle size, optimal viscoelasticity, and natural volumizing effects, making it a reliable choice for safe and effective aesthetic procedures.

IMCAS 2025 is more than just a product exhibition—it serves as a platform for advancing the safety and efficacy of medical aesthetic treatments. This lecture is expected to further intensify discussions on ensuring the safety of filler procedures.